This is a Validated Antibody Database (VAD) review about mouse Mark4, based on 4 published articles (read how Labome selects the articles), using Mark4 antibody in all methods. It is aimed to help Labome visitors find the most suited Mark4 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
Mark4 synonym: 2410090P21Rik; C79806; Markl1; MAP/microtubule affinity-regulating kinase 4; MAP/microtubule affinity-regulating kinase 4L; MARK4 serine/threonine protein kinase
Knockout validation
Cell Signaling Technology rabbit polyclonal |
| Cell Signaling Technology Mark4 antibody (Cell Signaling, 4834) was used in western blot knockout validation on human samples (fig 3b). EMBO Rep (2017) ncbi |
Proteintech Group
rabbit polyclonal |
| In order to explore how laminin2 in the basement membrane modulates the blood testis barrier dynamics during spermatogenesis, Proteintech Group Mark4 antibody (Proteintech, 20174-1-AP) was used in western blot on rat samples at 1:2000 (fig 3a). FASEB J (2017) ncbi |
Cell Signaling Technology
rabbit polyclonal |
| Cell Signaling Technology Mark4 antibody (Cell Signaling, 4834) was used in proximity ligation assay on mouse samples (fig s8a). Nat Commun (2017) ncbi |
rabbit polyclonal |
| Cell Signaling Technology Mark4 antibody (Cell Signaling, 4834) was used in western blot knockout validation on human samples (fig 3b). EMBO Rep (2017) ncbi |
rabbit polyclonal |
| In order to study the role of EB1 in tubulin and actin cytoskeletal networks at the sertoli cell blood-testis barrier, Cell Signaling Technology Mark4 antibody (Cell Signaling Technology, 4834S) was used in western blot on rat samples at 1:500. Endocrinology (2015) ncbi |
Articles Reviewed
contribute
- If you are aware of any publication with knockout studies validating a monoclonal or recombinant antibody, either purchased from a supplier or developed by the author(s), please notify us through feedback.
questions and comments